Circular Genomics
Personalized Diagnostics for Neurological Disorders
An industry first, Circular Genomics is developing a platform leveraging a novel and stable form of RNA, known as circular RNAs, as biomarkers to help patients suffering from psychiatric and neurological disorders find the most effective personalized treatment. The company’s first product aims to predict a patient’s sensitivity to anti-depressants before treatment, allowing clinicians to make better choices and provide faster, more effective relief for patients.
Latest Circular Genomics News
Circular Genomics Unveils Its CircPATH™ Platform Following Landmark Nature Medicine Study Demonstrating Breakthrough Performance in Early Detection of Alzheimer’s Disease
SAN DIEGO, July 2, 2026 /PRNewswire/ — Circular Genomics today announced the launch of CircPATH™, the company’s proprietary circular RNA discovery and validation engine, following the publication of landmark findings in…
Global Alzheimer’s Platform Foundation Announces Strategic Collaboration and Partnership with Circular Genomics for the Transformative Bio-Hermes-001 Study
Washington D.C., May 28, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to announce a collaboration with the Circular Genomics, a biotechnology company revolutionizing neurological and psychiatric precision medicine,…
-
Circular Genomics and Vitazi.ai Forge Strategic Alliance to Develop First-in-Class Multimodal Workflow for Early Alzheimer’s Detection
SAN DIEGO, April 29, 2026 /PRNewswire/ — Circular Genomics, the precision neurology leader pioneering circular RNA (circRNA)-based molecular diagnostics, today announced a strategic alliance with Vitazi.ai, an innovator in AI-powered…
-
Circular Genomics Strengthens Scientific Advisory Board with the Addition of Esteemed Alzheimer’s Experts
Michael Weiner, MD and Timothy Hohman, PhD, bring decades of experience in neurological diseases with a focus on Alzheimer’s disease SAN DIEGO, Dec. 8, 2025 /PRNewswire/ — Circular Genomics, a…
-
Circular Genomics Announces Closure of $15 Million Series A Financing to Advance First-in-Class Circular RNA Platform for Early Detection of Alzheimer’s Disease
SAN DIEGO, Dec. 1, 2025 /PRNewswire/ — Circular Genomics, Inc., the world-leading developer of circular RNA-based precision medicine tools for neurology and psychiatry, today announced the successful closure of a $15…
-
Circular Genomics to Unveil New Data Highlighting Circular RNAs as a Transformative New Class of Blood-Based Biomarkers for Alzheimer’s Disease at CTAD 2025
New clinical data highlights circular RNAs (circRNAs) as a novel, non-invasive blood biomarker platform for the early detection of Alzheimer’s Disease (AD). The research demonstrates that circRNAs offer comprehensive insights into…
Circular Genomics Receives $250K Investment from the Alzheimer’s Drug Discovery Foundation (ADDF) to Advance First-in-Class Circular RNA Blood-Based Biomarker Tests for the Early Detection of Alzheimer’s Disease
SAN DIEGO, July 8, 2025 /PRNewswire/ — Circular Genomics, Inc., a global leader in circular RNA (circRNA) biomarkers for precision neurology and psychiatry, today announced it has received a $250,000…
-
Circular Genomics Joins Lilly Gateway Labs in San Diego to Develop Its Best-In-Class Circular RNA Platform for the Diagnosis and Prognosis of Alzheimer’s Disease
SAN DIEGO, March 17, 2025 /PRNewswire/ — Circular Genomics, a global leader in circular RNA (circRNA) biomarkers for precision neurology and psychiatry, today announced it is moving the company’s headquarters…
-
Circular Genomics Announces Launch of MindLight™, the First SSRI Antidepressant Response Test Using Brain-Derived Biomarkers
ALBUQUERQUE, N.M., Sept. 16, 2024 /PRNewswire/ — Circular Genomics, the global leader in circular RNA biomarkers for precision psychiatry and neurology, today announced the launch of MindLight, the first circular…
-
Circular Genomics Adds Dr. Michael Ackermann, PhD, MBA to its Scientific Advisory Board
ALBUQUERQUE, N.M., March 18, 2024 /PRNewswire/ — Circular Genomics, the global leader in circular RNA biomarkers for precision psychiatry and neurology, today announced the addition of Michael F. Ackermann, PhD,…